 ZURICH-SCHLIEREN, Switzerland, Aug. 09, 2021 GLOBE NEWSWIRE -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG SIX: MOLN; NASDAQ: MOLN, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, announced today the receipt of notification from its partner, AbbVie Inc., regarding its termination of the license and collaboration agreement for the investigational drug abicipar pegol for the treatment of neovascular age-related macular degeneration nAMD and Diabetic Macular Edema DME. As such, Molecular Partners will regain the development and commercial rights of abicipar on a worldwide basis. 